BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 19995709)

  • 1. Combined perioperative plasma endoglin and VEGF--a assessment in colorectal cancer patients.
    Myśliwiec P; Pawlak K; Kukliński A; Kedra B
    Folia Histochem Cytobiol; 2009; 47(2):231-6. PubMed ID: 19995709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined perioperative plasma endoglin and VEGF-A assessment in colorectal cancer patients.
    Myśliwiec P; Pawlak K; Kukliński A; Kedra B
    Folia Histochem Cytobiol; 2008; 46(4):487-92. PubMed ID: 19141403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated plasma endoglin (CD105) predicts decreased response and survival in a metastatic breast cancer trial of hormone therapy.
    Vo MN; Evans M; Leitzel K; Ali SM; Wilson M; Demers L; Evans DB; Lipton A
    Breast Cancer Res Treat; 2010 Feb; 119(3):767-71. PubMed ID: 19115106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble angiogenesis markers in gastric tumor patients.
    Mysliwiec P; Pawlak K; Bandurski R; Kedra B
    Folia Histochem Cytobiol; 2009; 47(1):81-6. PubMed ID: 19419943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients.
    Pappa CA; Alexandrakis MG; Boula A; Psarakis FE; Kolovou A; Bantouna V; Stavroulaki E; Tsirakis G
    Hematol Oncol; 2013 Dec; 31(4):201-5. PubMed ID: 23576184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative serum levels of soluble endoglin for prediction of recurrence in stage III colorectal cancer patients.
    Gomceli I; Tez M; Bostanci EB; Turhan N; Kemik AS; Akoglu M
    Acta Medica (Hradec Kralove); 2012; 55(2):74-7. PubMed ID: 23101269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma VEGF-A and its soluble receptor R1 correlate with the clinical stage of colorectal cancer.
    Myśliwiec P; Piotrowski Z; Zalewski B; Kukliński A; Pawlak K
    Rocz Akad Med Bialymst; 2004; 49 Suppl 1():85-7. PubMed ID: 15638384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor and endoglin (CD-105) in gastric cancer.
    Nikiteas NI; Tzanakis N; Theodoropoulos G; Atsaves V; Christoni Z; Karakitsos P; Lazaris AC; Papachristodoulou A; Klonaris C; Gazouli M
    Gastric Cancer; 2007; 10(1):12-7. PubMed ID: 17334712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relevance of Endoglin (CD105) VEGF and p53 with invasion metastasis and prognosis of laryngeal carcinoma].
    Li Q; Zhang B; Peng P
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Dec; 21(24):1114-7. PubMed ID: 18330257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis.
    Li C; Gardy R; Seon BK; Duff SE; Abdalla S; Renehan A; O'Dwyer ST; Haboubi N; Kumar S
    Br J Cancer; 2003 May; 88(9):1424-31. PubMed ID: 12778073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endoglin (CD105) and VEGF as potential angiogenic and dissemination markers for colorectal cancer.
    Nogués A; Gallardo-Vara E; Zafra MP; Mate P; Marijuan JL; Alonso A; Botella LM; Prieto MI
    World J Surg Oncol; 2020 May; 18(1):99. PubMed ID: 32434528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Endoglin and Vascular Endothelial Growth Factor as Prognostic Markers in Experimental Colorectal Cancer.
    Ilhan N; Gungor H; Gul HF; Eroksuz H
    Anticancer Res; 2016 Aug; 36(8):3953-9. PubMed ID: 27466499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin.
    Takahashi N; Kawanishi-Tabata R; Haba A; Tabata M; Haruta Y; Tsai H; Seon BK
    Clin Cancer Res; 2001 Mar; 7(3):524-32. PubMed ID: 11297243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer.
    Tsai WS; Changchien CR; Yeh CY; Chen JS; Tang R; Chiang JM; Hsieh PS; Fan CW; Wang JY
    Dis Colon Rectum; 2006 Jun; 49(6):883-94. PubMed ID: 16741643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma.
    Saarelainen SK; Staff S; Peltonen N; Lehtimäki T; Isola J; Kujala PM; Vuento MH; Mäenpää JU
    Tumour Biol; 2014 May; 35(5):4651-7. PubMed ID: 24420153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma.
    Saad RS; El-Gohary Y; Memari E; Liu YL; Silverman JF
    Hum Pathol; 2005 Sep; 36(9):955-61. PubMed ID: 16153457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The relationship between plasma level of VEGF or soluble Flt-1 and efficacy of hepatic arterial chemotherapy in patients with liver metastasis of colorectal cancer].
    Gonda T; Okada N; Nakada H; Yokoyama M; Miyazaki T; Ishibashi K; Ishida H; Matsumoto Y; Miura T
    Gan To Kagaku Ryoho; 2006 Nov; 33(12):1841-4. PubMed ID: 17212123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma.
    El-Gohary YM; Silverman JF; Olson PR; Liu YL; Cohen JK; Miller R; Saad RS
    Am J Clin Pathol; 2007 Apr; 127(4):572-9. PubMed ID: 17369132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy.
    Svatek RS; Karam JA; Roehrborn CG; Karakiewicz PI; Slawin KM; Shariat SF
    Clin Cancer Res; 2008 Jun; 14(11):3362-6. PubMed ID: 18519764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor and endoglin expression in colorectal cancer.
    Dassoulas K; Gazouli M; Theodoropoulos G; Christoni Z; Rizos S; Zisi-Serbetzoglou A; Glava C; Karantanos T; Klonaris C; Karakitsos P
    J Cancer Res Clin Oncol; 2010 May; 136(5):703-8. PubMed ID: 19890661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.